172 related articles for article (PubMed ID: 32157993)
21. Risk factors for erythema nodosum leprosum.
Manandhar R; LeMaster JW; Roche PW
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):270-8. PubMed ID: 10575406
[TBL] [Abstract][Full Text] [Related]
22. [Current guidelines for leprosy treatment].
Flageul B
Bull Soc Pathol Exot; 2003 Jan; 96(5):357-61. PubMed ID: 15015839
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states.
Sarno EN; Grau GE; Vieira LM; Nery JA
Clin Exp Immunol; 1991 Apr; 84(1):103-8. PubMed ID: 2015700
[TBL] [Abstract][Full Text] [Related]
24. Recognizing and managing the immunologic reactions in leprosy.
Kamath S; Vaccaro SA; Rea TH; Ochoa MT
J Am Acad Dermatol; 2014 Oct; 71(4):795-803. PubMed ID: 24767732
[TBL] [Abstract][Full Text] [Related]
25. Effect of rhuIFN-gamma treatment in multibacillary leprosy patients.
Sampaio EP; Malta AM; Sarno EN; Kaplan G
Int J Lepr Other Mycobact Dis; 1996 Sep; 64(3):268-73. PubMed ID: 8862260
[TBL] [Abstract][Full Text] [Related]
26. Erythema nodosum leprosum in Nepal: a retrospective study of clinical features and response to treatment with prednisolone or thalidomide.
Feuth M; Brandsma JW; Faber WR; Bhattarai B; Feuth T; Anderson AM
Lepr Rev; 2008 Sep; 79(3):254-69. PubMed ID: 19009975
[TBL] [Abstract][Full Text] [Related]
27. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
28. IgG antibody subclasses, tumor necrosis factor and IFN-gamma levels in patients with type II lepra reaction on thalidomide treatment.
Partida-Sanchez S; Favila-Castillo L; Pedraza-Sanchez S; Gomez-Melgar M; Saul A; Estrada-Parra S; Estrada-Garcia I
Int Arch Allergy Immunol; 1998 May; 116(1):60-6. PubMed ID: 9623511
[TBL] [Abstract][Full Text] [Related]
29. Delayed-type hypersensitivity reactions followed by erythema nodosum leprosum.
Rea TH; Sieling PA
Int J Lepr Other Mycobact Dis; 1998 Sep; 66(3):316-27. PubMed ID: 9934358
[TBL] [Abstract][Full Text] [Related]
30. Utility and limitations of serodiagnostic tests in monitoring the response to treatment of leprosy patients.
Duthie MS; Roferos FO; Abellana JF; Taborada T; Sanchez R; Maghanoy A; Balagon MF
Diagn Microbiol Infect Dis; 2020 Apr; 96(4):114984. PubMed ID: 31954594
[TBL] [Abstract][Full Text] [Related]
31. Case Report: A Case Series of Immunobiological Therapy (Anti-TNF-α) for Patients With Erythema Nodosum Leprosum.
Mendes AFM; Gomes CM; Kurizky PS; Ianhez M
Front Med (Lausanne); 2022; 9():879527. PubMed ID: 35814767
[TBL] [Abstract][Full Text] [Related]
32. Type 1 (reversal) lepra reaction in borderline leprosy with unusual clinical presentation--a case report.
Kar HK; Saxena AK; Jain RK; Sharma AK
Indian J Lepr; 1987; 59(2):219-22. PubMed ID: 3655433
[TBL] [Abstract][Full Text] [Related]
33. Development of leprosy in a patient with rheumatoid arthritis during treatment with etanercept: a case report.
Lluch P; Urruticoechea A; Lluch J; Moll MC; Matos M; Benet JM; Ene L; Cañete JD
Semin Arthritis Rheum; 2012 Oct; 42(2):127-30. PubMed ID: 22542278
[TBL] [Abstract][Full Text] [Related]
34. A dissimulate presentation of histoid Hansen's disease in the form of erythema nodosum leprosum.
Pathania V; Oberoi B; Baveja S; Shelly D; Venugopal R; Shankar P
Int J Mycobacteriol; 2019; 8(2):208-210. PubMed ID: 31210170
[TBL] [Abstract][Full Text] [Related]
35. The Effects of Prednisolone Treatment on Cytokine Expression in Patients with Erythema Nodosum Leprosum Reactions.
Negera E; Walker SL; Bobosha K; Bekele Y; Endale B; Tarekegn A; Abebe M; Aseffa A; Dockrell HM; Lockwood DN
Front Immunol; 2018; 9():189. PubMed ID: 29479352
[TBL] [Abstract][Full Text] [Related]
36. Does clofazimine prevent erythema nodosum leprosum (ENL) in leprosy? A retrospective study, comparing the experience of multibacillary patients receiving either 12 or 24 months WHO-MDT.
Balagon M; Saunderson PR; Gelber RH
Lepr Rev; 2011 Sep; 82(3):213-21. PubMed ID: 22125929
[TBL] [Abstract][Full Text] [Related]
37. International workshop on erythema nodosum leprosum (ENL)--consensus report; the formation of ENLIST, the ENL international study group.
Walker SL; Saunderson P; Kahawita IP; Lockwood DN
Lepr Rev; 2012 Dec; 83(4):396-407. PubMed ID: 23614260
[No Abstract] [Full Text] [Related]
38. Erythema Nodosum Leprosum: Update and challenges on the treatment of a neglected condition.
Costa PDSS; Fraga LR; Kowalski TW; Daxbacher ELR; Schuler-Faccini L; Vianna FSL
Acta Trop; 2018 Jul; 183():134-141. PubMed ID: 29474830
[TBL] [Abstract][Full Text] [Related]
39. Differential immunoglobulin and complement levels in leprosy prior to development of reversal reaction and erythema nodosum leprosum.
Amorim FM; Nobre ML; Nascimento LS; Miranda AM; Monteiro GRG; Freire-Neto FP; Queiroz MDCP; Queiroz JW; Duthie MS; Costa MR; Reed SG; Johnson WD; Dupnik KM; Jeronimo SMB
PLoS Negl Trop Dis; 2019 Jan; 13(1):e0007089. PubMed ID: 30689631
[TBL] [Abstract][Full Text] [Related]
40. The -308 bp TNF gene polymorphism influences tumor necrosis factor expression in leprosy patients in Bahia State, Brazil.
Oliveira JM; Rêgo JL; de Lima Santana N; Braz M; Jamieson SE; Vieira TS; Magalhães TL; Machado PRL; Blackwell JM; Castellucci LC
Infect Genet Evol; 2016 Apr; 39():147-154. PubMed ID: 26829382
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
